Introduction
Chronic myeloid leukemia (CML) is characterized by the reciprocal chromosomal translocation t(9;22)(q34;q11) resulting in the formation of the Philadelphia chromosome (Ph). This encodes the constitutively active Bcr-Abl tyrosine kinase, which profoundly affects proliferation, apoptosis and cell adhesion signaling pathways. 1, 2 The majority of patients are diagnosed in chronic phase (CP), showing an expansion of myeloid lineage cells that are maintained by a rare subset of CD34 + /CD38leukemic stem cells (LSCs). 1, 2 Refractoriness of these LSCs to therapy may result in progression to blast crisis (BC). BC-CML is characterized by differentiation arrest and a disease more akin to that of an acute leukemia. 1, 2 CML evolved as a paradigm for targeted therapy as treatment with imatinib, a small molecule Bcr-Abl tyrosine kinase inhibitor (TKI), significantly improved the estimated overall survival in CP-CML patients to 85% at 8 years. 3 Furthermore, more potent second generation TKIs, such as nilotinib 4 and dasatinib, 5 induce faster and higher major molecular response (MMR) rates. Nevertheless, LSCs are thought to be insensitive to TKI therapy, 6, 7 and persist in CML patients, even in those with sustained complete molecular response (CMR). 8, 9 This is supported by the observation of molecular relapse after cessation of imatinib in 61-66% of CML patients, previously in CMR. 10, 11 Thus, current research efforts aim to develop additional therapies to target these TKI-refractory CML LSCs.
For personal use only. on April 15, 2017. by guest www.bloodjournal.org From In addition to other proposed mechanisms, we and others have previously shown that cytokine-induced JAK/STAT survival signaling potently mediates resistance to TKIs in CML CD34 + progenitors. [12] [13] [14] Also, CML CD34 + and CD34 + /CD38cells are thought to produce IL-3 and G-CSF providing an autocrine activation loop that contributes to their innate resistance. [15] [16] [17] Accordingly, the concept of targeting CML leukemic stem and progenitor cells (LSPCs) at the cytokine receptor level might be a promising approach, especially since some cytokine receptors are overexpressed in stem cells of certain leukemias. One example is CD123 (IL-3 receptor α subunit), an established LSC marker in acute myeloid leukemia (AML). 18, 19 However, in CML cell surface markers that distinguish normal and leukemic stem cells remain elusive.
The IL-3 receptor consists of a ligand-binding α subunit (CD123) and the primary signaling subunit β c (CD131). 20,21 IL-3 signaling is known to stimulate cell cycle progression in early haematopoietic progenitors and promote differentiation while inhibiting apoptosis in various haematopoietic cells. 20,21 CD123 advanced as a promising therapeutic monoclonal antibody (mAb) target in AML as treatment with the IL-3-neutralizing antibody 7G3 22 reduced AML LSC homing, engraftment and self-renewal ability, and improved the survival of xenografted NOD/SCID mice with minimal effect on the engraftment of normal bone marrow cells. 23 This prompted the clinical development of CSL362, a humanized form of 7G3, which was additionally Fc-engineered to achieve maximal antibody-dependent cell-mediated cytotoxicity (ADCC). 24 Here we show that, compared to normal donors, CD123 expression is significantly increased in CD34 + /CD38cells of both CP-and BC-CML patients and that CSL362
For personal use only. on April 15, 2017 . by guest www.bloodjournal.org From 5 is highly effective in blocking IL-3-stimulated rescue of TKI-induced cell death and mediating ADCC in CML LSPCs. To our knowledge this is the first report to investigate CD123 mAb targeting to eliminate CML LSPCs. 
CD34 + and NK cell isolation
CD34 + cells were isolated from MNCs by magnetically-activated cell sorting (MACS) using the human CD34 progenitor kit (Miltenyi Biotech, Auburn, CA). Cryopreservation and subsequent thawing and resting (1 h at 37°C) of isolated CML CD34 + cells ensured high purity (> 85%). The human NK cell isolation kit (Miltenyi Biotech) was used to isolate CML patients' and normal donors' NK cells by MACS.
Cell lines
MOLM-1 megakaryoblastic CML cells 25 and TF-1.8 erythroleukemia cells, lentivirally transduced to overexpress CD123 and GFP, were cultured in RPMI/10% FCS and RPMI/10% FCS supplemented with 2 ng/ml GM-CSF, respectively, at 37°C/5% CO 2 .
The murine stromal cell line AFT024, 26 
Flow cytometry
Fluorophore-conjugated antibodies for cell surface staining were from BD Biosciences (San Jose, CA; CD3, CD16, CD34, hCD45, CD56 and CD123), Invitrogen (Carlsbad, CA, mCD45) and BioLegend (San Diego, CA; CD38). To determine STAT5 phosphorylation in CML LSPCs, CD34 + cells, treated as indicated, were fixed and permeablized as described 12 and co-stained with BD Phosflow pY694 STAT5-Alexa 488, CD34-PE and CD38-Alexa 647. Data were acquired on a FC500 (Beckman Coulter, Miami, FL) and analyzed using FCS Express (De Novo Software, Los Angeles, CA). CP-CML CD34 + /CD38 lo subpopulations were sorted on a FACS Aria (BD Biosciences).
Cell viability assay
CML CD34 + cells, treated as indicated, were cultured for 72 h in serum-deprived medium (SDM), containing Iscove's Modification of Dulbecco Medium (IMDM) supplemented with 1% bovine serum albumin (BSA), 2 mM L-glutamine, 1 U/ml insulin, 0.2 mg/ml iron-saturated transferrin, 20 µg/ml low-density lipoproteins and 0.1 mM 2-mercaptoethanol. Cells were labeled with Annexin V-PE (BD Biosciences) For personal use only. on April 15, 2017. by guest www.bloodjournal.org From and 7-Aminoactinomycin D (7-AAD, Invitrogen) and analyzed by flow cytometry.
Double negative-populations defined viable cells.
Colony-forming unit (CFU) assay CD34 + cells, pre-treated as indicated, or sorted cell populations were plated in Methocult H4230 medium (Stem Cell Technologies, Vancouver, BC), containing 20 ng/ml of GM-CSF, G-CSF, IL-3, IL-6 and 50 ng/ml of SCF. CFU-granulocyte and macrophage (CFU-GM) and spontaneous burst forming unit-erythroid (BFU-E) colonies were counted after 14 days. To determine the replating capability, all colonies per dish were harvested, washed three times in PBS and 10 4 cells were replated into fresh methylcellulose culture medium. Secondary colonies were counted after a further 14-day-incubation.
Long-term culture-initiating cell (LTC-IC) assay
CD34 + cells, pre-treated as indicated, were plated in duplicates on AFT024 feeder cell layers (irradiated with 20 Gy) established in 24-well plates in MyeloCult H5100 (Stem Cell Technologies) freshly supplemented with 10 -6 M hydrocortisone. Cultures were maintained for 5 weeks at 37°C with weekly half-media changes, before seeding harvested cells into CFU assays.
CFSE proliferation assay
To assess proliferation, CP-CML CD34 + cells were labeled with 1 µM 5-(and 6-) 
Murine engraftment studies
Mice were maintained using protocols and conditions approved by the Animal Care and Ethics Committee of SA PATHOLOGY/CHN. Transplantation of human cells into female NOD/SCID (NOD.CB17-Prkdc scid /J) mice was performed as previously described. 23 Briefly, thawed BC-CML MNCs (5x10 6 /mouse) were incubated with CSL362 or BM4 isotype control antibody (1 µg/ml) in the presence of purified NK cells (E:T 1:1), with or without 1 µM nilotinib, overnight at 37°C in RPMI/5% FCS before tail vein injection into sub-lethally irradiated (275 cGy) mice. Engraftment was 
Statistical analysis
Graphpad Prism (GraphPad Software, La Jolla, CA) was used for graphs and data are presented as mean ± SE or individual data points. Statistical analysis was performed in Sigma plot (San Jose, CA) and t-tests or Mann-Whitney tests were used as required.
Results

CML CD34 + /CD38cells express elevated levels of CD123
BC-CML CD34 + cells showed a higher frequency of CD123 + cells (77.5% vs. 45.5%; p=0.007) and an increase in CD123-PE mean fluorescence intensity (MFI; 7.3 vs.
2.3; p=0.001) compared to normal CD34 + cells, while in CD34 + cells from CP-CML patients a trend towards increased CD123 expression was detected ( Figure 1A , gating demonstrated in supplemental Figure 1 ). In the CD34 + /CD38subset, which is enriched for LSCs, the percentage of CD123 + cells and CD123 expression levels were significantly elevated (p<0.01) in samples of both de novo CP-CML (53.0% CD123 + /MFI 2.4) and BC-CML patients (73.2% CD123 + /MFI 8.9) compared to normal donors (20.3% CD123 + /MFI 1.6; Figure 1B ). The observed CD123 expression levels were similar to those seen in primitive AML cells (72.4% CD123 + /MFI 5.6; Figure 1B ).
Interestingly, CD123 expression was consistently higher in BC-CML than CP-CML samples, confirmed by an increase in CD123 expression with disease progression in matched samples ( Figure 1C ). High CD123 expression was not only noted in myeloid blast crisis CD34 + /CD38cells, but also in three of three lymphoid (94.1% ± 1.4% CD123 + /MFI 20.9 ± 15.2) and one of two biphenotypic (74.7% CD123 + /MFI 2.6 and 25.2% CD123 + /MFI 2.2, respectively) BC-CML cases.
In addition, IL-3 plasma levels in CP-CML patients tended to be higher at diagnosis (4.3 ± 1.2 pg/ml) relative to plasma samples of healthy donors (1.1 ± 0.6 pg/ml), but were reduced in matched samples of TKI-treated patients (2.0 ± 0.5 pg/ml; Figure   1D ).
CD34 + /CD38 lo /CD123 + CP-CML LSPCs show in vitro self-renewal capacity
We compared the colony replating and LTC-IC potential, assays for primitive progenitors that can maintain long-term culture and can be used as surrogate markers of self-renewal capacity, of FACS-sorted CD123-positive and -negative CD34 + /CD38 lo subpopulations (supplemental Figure 2 ). While the CD123 + CD34 + /CD38 lo subset formed more primary colonies (147.5 vs. 72.4 per 1000 cells seeded, p=0.06), these cells gave rise to less secondary colonies upon replating (42.9 vs. 84.9 per 10000 cells seeded, p=0.1) compared to CD123 -CD34 + /CD38 lo cells ( Figure 2A) . Similarly, LTC-IC colony numbers derived from CD123 + primitive CP-CML cells were lower than those from CD123counterparts (100.3 vs. 137.4 per 1000 cells seeded, p=0.06; Figure 2B ). However, BCR-ABL1 FISH revealed the presence of normal (Ph -) primitive cells specifically within the CD123 -CD34 + /CD38 lo fraction and CFU and LTC-IC colonies ( Figure 2C ).
CSL362 prevents IL-3-mediated rescue of dasatinib-treated CP-CML LSPCs
Initial titration experiments ascertained optimal concentrations of IL-3 (1 ng/ml) required to rescue dasatinib-induced cell death and of CSL362 (10 µg/ml) needed to neutralize IL-3-mediated survival and signaling (supplemental Figure 3 ). As anticipated, IL-3 potently enhanced the survival of control DMSO-treated (152.2% vs.
100%, p=0.03) and dasatinib-exposed (106.5% vs. 47.1%, p=0.02) CP-CML CD34 + cells ( Figure 3A) , and induced proliferation thereby reducing the percentage of undivided cells ( Figure 3B ). Accordingly, the numbers of CFUs (81.2% vs. 34.5%, p=0.004) and LTC-ICs (64.8% vs. 35.8%, p=0.4) were increased in IL-3-and dasatinib-co-treated samples compared to dasatinib alone ( Figure 3C -D).
Importantly, CSL362, but not the matched isotype control antibody BM4, completely abrogated IL-3-mediated effects ( Figure 3A-D) , including the rescue of dasatinib-treated CP-CML CFUs (33.1% vs. 81.2%, p=0.005) and LTC-ICs (28.8% vs. 64.8% on average, p=0.3). Both CFU and LTC-IC colonies were predominantly Ph + (93.8%, n=4 and 95.5%, n=2, respectively). In the absence of exogenous IL-3, CSL362 did not affect CML CFUs or LTC-ICs (data not shown).
There are several similarities in Bcr-Abl and IL-3 signaling with STAT5 activation being one point of convergence. 29 STAT5 phospho-flow cytometry revealed that the observed effects of IL-3 and CSL362 on CP-CML LSPC survival were mirrored by STAT5 phosphorylation levels in CP-CML CD34 + and CD34 + /CD38cells ( Figure 3E -F). Importantly, additive effects of combined dasatinib and CSL362 treatment, superseding the impact of dasatinib alone, in reducing STAT5 phosphorylation were seen in IL-3-stimulated cells (32.0% vs. 162.6%, p=0.02 for CD34 + cells and 24.7% vs. 57.7%, p=0.01 for CD34 + /CD38cells).
Combination of CSL362 even with low doses of dasatinib was able to neutralize IL-3rescue in CP-CML CD34 + progenitors, evident from reduced numbers of viable CD34 + cells and CFUs (60.7% vs. 81.3% of control at 0.1 nM dasatinib, p=0.03, supplemental Figure 4 ). In the presence of multiple growth factors (5GF), likely to be present in the bone marrow microenvironment, 30 CSL362 treatment did not affect dasatinib-induced cell death at any dose (supplemental Figure 4 ).
CSL362 mediates specific NK cell-dependent lysis of CD123 + CML LSPCs
Firstly, CSL362-mediated ADCC was assessed in 4h LDH release assays using NK cells from healthy donors as effectors and CD123/TF-1 and MOLM-1 cells with high exogenous and endogenous CD123 expression, respectively, as target cells.
CSL362 mediated dose-dependent cell lysis (52.4% and 26.9% lysis at 0.1 µg/ml For personal use only. on April 15, 2017. by guest www.bloodjournal.org From 14 CSL362 for CD123/TF-1 and MOLM-1, respectively), while CSL360, a humanmouse chimeric variant of 7G3 devoid of an ADCC-enhancing modification, 24 did not (1.3% MOLM-1 cell lysis; Figure 4A ). Importantly, progenitors from both CP-and BC-CML patients were killed by CSL362-mediated ADCC (37.5% lysis on average with 0.1 µg/ml CSL362; Figure 4B ). This corresponded to a reduction in CFUs to 30.0% on average in CP-CML CD34 + cells ( Figure 4C ) and to 5.3% and 29.1%, respectively, in two BC-CML patient samples tested ( Figure 4D ). Also, CFUs of FACS-sorted CD34 + /CD38 + and CD34 + /CD38 lo cells of a representative CP-CML patient were decreased to a similar extent when subjected to CSL362-mediated ADCC (supplemental Figure 5 ), suggesting that both subsets may be equally targeted. Accordingly, flow cytometry analysis revealed specific depletion of CD123expressing CD34 + and CD34 + /CD38cells from CP-CML and BC-CML patients as a result of CSL362-mediated ADCC ( Figure 4E -F).
To assess the effect of CSL362 on leukemia-initiating cells, BC-CML patient cells were injected into sub-lethally irradiated, immune-compromised NOD/SCID mice.
Indeed, CSL362 ex vivo pre-treatment in the presence of NK cells reduced the leukemic cell engraftment of two individual BC-CML patient samples ( Figure 5 ).
Despite variable levels of engraftment between the patient samples, both FISH
(100% of human engrafted cells were Ph + for BC-CML 4) and BCR-ABL1 quantitative PCR (96.0 ± 3.9% IS for BC-CML 4 and 104.1 ± 6.4% IS for BC-CML 5) ascertained the leukemic nature of the engrafted cells independent of treatment.
Moreover, flow cytometry studies showed that most of the engrafted hCD45 + cells were CD123 + ( Figure 5A ).
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Autologous NK cells are potent effectors of CSL362-mediated ADCC in CP-
CML LSPCs
Next, the efficiency of autologous NK cells of CML patients (Table 1) , who achieved at least a complete cytogenetic response (CCyR), in mounting a CSL362-mediated ADCC response against matching cryo-preserved CD34 + cells, collected at diagnosis, was tested. Remarkably, autologous CML patient NK cells induced CSL362-mediated cytotoxicity to the same extent as allogeneic healthy donor NK cells since the numbers of remaining CFUs were equivalent (28.0% vs. 34.9%; Figure 6A ) and CD123-positive CD34 + and CD34 + /CD38populations were similarly depleted (supplemental Figure 6 ). Of note, autologous NK cells from dasatinibtreated patients appeared to be at least equally, if not more, potent compared to those of imatinib-treated patients (15.5% CFUs remaining, n=2 vs. 36.4% CFUs remaining, n=3).
To determine the effect of CSL362-mediated ADCC on normal progenitor and stem cells, matched healthy donor NK and CD34 + cells were used. Both, autologous and allogeneic NK cells conferred CSL362-mediated ADCC ( Figure 6B ), but more importantly, the number of remaining normal CFUs was higher than that of CML CFUs (56.5% vs. 28%, p=0.008). Moreover, normal LTC-ICs were also less affected than CML LTC-ICs (59.8% vs. 30.3%, p=0.072, Figure 6C ). In addition, while CML CFUs were predominantly Ph + with or without CSL362-mediated ADCC (83.4% vs. 89.4%, n=4), the LTC-IC colonies remaining after CSL362-mediated ADCC of two of the three CP-CML patients were predominantly Ph-negative ( Table 2) To mimic the potential clinical setting of sequential TKI/CSL362 therapy, CP-CML CD34 + were pre-treated with nilotinib for 48 h and consecutively subjected to CSL362-mediated ADCC at an E:T ratio of 1:1 overnight in the presence of nilotinib.
Importantly, this combination resulted in a significantly greater reduction in CFUs (to 12.7% remaining, p<0.05) compared to either CSL362-mediated ADCC (28.7%) or nilotinib (38.6%) alone ( Figure 7A ). This additive effect was not observed when the same experiment was performed with normal CD34 + cells (with ADCC alone 55.2%, with nilotinib alone 85.9% and in the combination of both 58.6% CFUs remaining; Figure 7B ). 
Discussion
Although first and second generation TKIs revolutionized the CML treatment, elimination of the disease seems elusive for the majority of patients to date likely due to residual CML LSCs. 6, 7, 10 While CD123 is a recognized specific marker for AML CD34 + /CD38stem cells 18,19 and has been suggested as a CML LSPC marker, 31 its role in CML has not been elucidated in detail. In this study, we demonstrate that CD123 expression is significantly higher in CD34 + /CD38cells from both CP-and BC-CML patients as well as in CD34 + BC-CML cells compared to normal donors.
Interestingly, CD123 expression in LSPCs increased with progression from chronic to blast phase CML, in line with previous reports associating the IL-3RA gene 32 and an expansion of CD34 + CD38 + CD123 + CD45RA + granulocyte-macrophage progenitors (GMPs) 33 with BC-CML. As targeting AML LSCs with the specific CD123 mAbs 7G3 23 and CSL362 24,34 has shown efficacy in vitro and in vivo, we further investigated the potential of CSL362 to deplete CML LSPCs. We show that CSL362 efficiently induces NK cell-dependent lysis of CD123-expressing CD34 + and CD34 + /CD38 -CP-and BC-CML cells and also neutralizes IL-3 function in CP-CML LSPCs.
In BC-CML CD123 + GMPs, thought to constitute the leukemic, self-renewing stem cell population, 33 represent the vast majority of CD34 + cells and were shown to be competent in maintaining leukemic CD123 + populations in engrafted immunocompromised mice, 35 resembling the situation in AML. 18 Our BC-CML engraftment studies in NOD/SCID mice also confirmed this notion. In the CP-CML setting, our studies comparing CD123-positive and -negative CD34 + /CD38 lo subsets yielded the unexpected result that the CD123subpopulation showed higher replating and LTC-For personal use only. on April 15, 2017. by guest www.bloodjournal.org From IC potential than the CD123 + subset. However, the enrichment of normal primitive cells in the CD123subpopulation could be responsible for the higher replating and LTC-IC frequency as Bcr-Abl + stem cells display reduced self-renewal ability compared to normal stem cells, 36 suggesting a similar in vitro self-renewal capacity of leukemic CD123 + and CD123 -CP-CML subsets. Clearly, murine studies evaluating the engraftment and serial transplantation ability of those cellular subsets are warranted to fully elucidate that question.
Apoptosis, proliferation, CFU and LTC-IC assays confirmed the ability of CSL362 to prevent IL-3-mediated protection against dasatinib-induced cell death in CML LSPCs. However, this effect was lost in the presence of other cytokines, including GM-CSF and G-CSF, consistent with the implication of other cytokines in TKI resistance. 12, 13 Nevertheless, our experiments validated the potential of targeting CD123 + CML LSPCs with an anti-CD123 mAb.
CSL362 acts via a second, potentially more clinically relevant, mechanism by selectively inducing NK cell-dependent killing of CD123-expressing CML LSPCs. This is demonstrated by increased target cell lysis, reduction of CFUs and LTC-ICs, selective depletion of CD123 + CD34 + and CD34 + /CD38subpopulations and reduction of leukemic engraftment in mice. As NK cell function may be reduced in CML, 37 we questioned if CML patients' NK cells were able to mount an effective CSL362-mediated ADCC response. Using NK cells from CML patients, who achieved at least CCyR, we could show that CSL362-induced ADCC is feasible in the autologous setting.
For personal use only. on April 15, 2017. by guest www.bloodjournal.org From Of note, dasatinib, in contrast to nilotinib, inhibited NK cell function in ADCC assays, most likely due to inhibition of Src family kinases as reported previously. 38, 39 In vivo dasatinib treatment, in contrast, might cause positive immune-modulatory effects, such as enhanced NK cell activity 40 and clonal expansion of large granular lymphocytes. 41, 42 Accordingly, NK cells isolated from two dasatinib-treated patients did not show any deficit in conferring CSL362-mediated ADCC.
An important consideration regarding the safety of CSL362 administration is the degree of selectivity for leukemic vs. normal stem cells. While we clearly demonstrated increased expression levels of CD123 in CML CD34 + /CD38cells, it was also evident that normal BM-derived progenitor and stem cells also express CD123, albeit at lower levels. Pre-clinical toxicity studies of CSL362 in cynomolgus monkeys demonstrated the safety of this antibody in vivo, where no obvious effects on hematopoiesis were observed. 43 Our own studies comparing the effects of CSL362-mediated ADCC indicated a preferential elimination of leukemic as opposed to normal CFUs and LTC-IC, but normal progenitor and stem cells are not completely spared. However, combination of TKI-and CSL362-dependent ADCCinduced cytotoxicity further increased selective targeting of CML over normal progenitors.
At which disease stage would it be most sensible to introduce CSL362 treatment?
The majority of CML patients require long-term TKI therapy, 10 associated with multiple concerns, such as development of resistance and tolerability issues.
CSL362 treatment could be used to consolidate the TKI-induced molecular response in CP-CML patients and thus increase the chances of maintaining CMR off TKI For personal use only. on April 15, 2017. by guest www.bloodjournal.org From therapy. Moreover, CD123 + GMPs, expanded in BC-CML and imatinib resistant CML patients, 33 represent excellent CSL362 targets. The reduction in murine engraftment of BC-CML cells by CSL362-mediated ADCC alone or in combination with nilotinib further substantiates this point. Potentially, the combination of TKI therapy and CSL362 may more effectively eliminate these progenitors in vivo than TKI treatment alone. However, NK cell competency during active disease stages remains to be ascertained. Of note, elevated CD123 expression was not only detected in CD34 + cells of patients in myeloid, but also in lymphoid blast crisis, consistent with high CD123 levels in B cell acute lymphocytic leukemia, including Ph + ALL. 44, 45 Another strategy targeting CD123, diphtheria toxin-conjugated IL-3, is currently under investigation for the treatment of MDS, AML, CML and Ph + ALL. 44, 46 However, while CD123 is an ideal target the balance between specificity and potential toxicity may be delicate. 47 JAK2 inhibition has also been suggested to overcome cytokinemediated resistance of CML progenitors, [12] [13] [14] but it may discriminate poorly between normal and leukemic progenitors. 14 Taken together, we have established that CD123 expression is elevated in CML CD34 + /CD38cells and evaluated a novel anti-CD123 mAb-based approach to further complement current CML treatment to specifically target LSPCs by selective ADCC-mediated lysis and blocking IL-3-mediated signaling. Importantly, CSL362mediated ADCC displayed selectivity for leukemic over normal progenitor and stem cells, which was further enhanced in CSL362/TKI combination treatments. Thus, 
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